Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN)..

JAMA. 2012 Apr 25;307(16):1717-26. doi: 10.1001/jama.2012.418. Epub 2012 Mar 24. Erratum in: JAMA. 2015 Jul 7;314(1):86.

2.

Intramyocardial autologous bone marrow cell transplantation for ischemic heart disease: a systematic review and meta-analysis of randomized controlled trials.

Tian T, Chen B, Xiao Y, Yang K, Zhou X.

Atherosclerosis. 2014 Apr;233(2):485-92. doi: 10.1016/j.atherosclerosis.2014.01.027. Epub 2014 Jan 23. Review.

PMID:
24530783
3.

Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials.

Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, Dawn B.

Circ Res. 2015 Aug 28;117(6):558-75. doi: 10.1161/CIRCRESAHA.114.304792. Epub 2015 Jul 9. Review.

5.

Intramyocardial Autologous Bone Marrow-derived Stem Cells Injection for Ischemic Heart Disease Ineligible for Revascularization: A Systematic Review and Meta-analysis.

Zhu K, Li J, Wang Y, Luo J, Zhang W, Guo C, Lai H, Wang C.

Arch Med Res. 2015 May;46(4):286-95. doi: 10.1016/j.arcmed.2015.06.001. Epub 2015 Jun 9. Review.

PMID:
26070842
6.

Additive value of adult bone-marrow-derived cell transplantation to conventional revascularization in chronic ischemic heart disease: a systemic review and meta-analysis.

Zhao Q, Ye X.

Expert Opin Biol Ther. 2011 Dec;11(12):1569-79. doi: 10.1517/14712598.2011.616491. Epub 2011 Oct 8. Review.

PMID:
21981749
7.

Current State of Stem Cell Therapy for Ischemic Heart Disease.

Povsic TJ.

Curr Cardiol Rep. 2016 Feb;18(2):17. doi: 10.1007/s11886-015-0693-6. Review.

PMID:
26768743
8.

Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure.

Roncalli J, Tongers J, Losordo DW.

Arch Cardiovasc Dis. 2010 Aug-Sep;103(8-9):469-76. doi: 10.1016/j.acvd.2010.04.006. Epub 2010 Jun 23. Review.

9.

Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis.

Nowbar AN, Mielewczik M, Karavassilis M, Dehbi HM, Shun-Shin MJ, Jones S, Howard JP, Cole GD, Francis DP; DAMASCENE writing group..

BMJ. 2014 Apr 28;348:g2688. doi: 10.1136/bmj.g2688. Review.

10.

Clinical effect of cardiac shock wave therapy on patients with ischaemic heart disease: a systematic review and meta-analysis.

Wang J, Zhou C, Liu L, Pan X, Guo T.

Eur J Clin Invest. 2015 Dec;45(12):1270-85. doi: 10.1111/eci.12546. Epub 2015 Nov 9. Review.

PMID:
26444429
11.

Gene targeting in ischemic heart disease and failure: translational and clinical studies.

Eckhouse SR, Jones JA, Spinale FG.

Biochem Pharmacol. 2013 Jan 1;85(1):1-11. doi: 10.1016/j.bcp.2012.08.018. Epub 2012 Aug 28. Review.

Supplemental Content

Support Center